Joseph M Pilewski
Overview
Explore the profile of Joseph M Pilewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
5907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vats K, Tian H, Singh K, Tyurina Y, Sparvero L, Tyurin V, et al.
J Clin Invest
. 2024 Nov;
135(2.
PMID: 39570671
Dysregulations of epithelial-immune interactions frequently culminate in chronic inflammatory diseases of the skin, lungs, kidneys, and gastrointestinal tract. Yet, the intraepithelial processes that initiate and perpetuate inflammation in these organs...
2.
Yue M, Weiner D, Gaietto K, Rosser F, Qoyawayma C, Manni M, et al.
Am J Respir Cell Mol Biol
. 2024 Jul;
71(6):730-739.
PMID: 39028582
Elexacaftor/tezacaftor/ivacaftor (ETI) has had a substantial positive impact for people living with cystic fibrosis (pwCF). However, there can be substantial variability in efficacy, and we lack adequate biomarkers to predict...
3.
Burdis N, Kapnadak S, Bartlett L, McElvaney O, Milinic T, Hee Wai T, et al.
BMC Pulm Med
. 2024 Jul;
24(1):348.
PMID: 39026320
Background: Outcomes for individuals with cystic fibrosis (CF) have improved due to highly effective modulator therapy (HEMT). However, lung transplant (LTx) remains an important treatment for people with advanced lung...
4.
Donaldson S, Corcoran T, Pilewski J, Laube B, Mogayzel P, Ceppe A, et al.
J Cyst Fibros
. 2024 Feb;
23(3):457-460.
PMID: 38355350
Many people with CF (pwCF) desire a reduction in inhaled treatment burden after initiation of elexacaftor/tezacaftor/ivacaftor. The randomized, open-label SIMPLIFY study showed that discontinuing hypertonic saline (HS) or dornase alfa...
5.
Gill E, Bartlett L, Milinic T, Burdis N, Pilewski J, Dunitz J, et al.
J Cyst Fibros
. 2023 Nov;
23(1):161-164.
PMID: 38008684
People with CF (PwCF), particularly those with advanced lung disease (ALD), experience frequent respiratory symptoms. A major CF breakthrough was the approval of elexacaftor/tezacaftor/ivacaftor (ETI) in 2019, which has been...
6.
Lu S, Chen K, Song K, Pilewski J, Gunn B, Poch K, et al.
Cell Rep Med
. 2023 Oct;
4(10):101210.
PMID: 37852181
Nearly one-half of patients with cystic fibrosis (CF) carry the homozygous F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene but exhibit variable lung function phenotypes. How adaptive...
7.
Donaldson S, Corcoran T, Pilewski J, Mogayzel P, Laube B, Boitet E, et al.
J Cyst Fibros
. 2023 Oct;
23(1):155-160.
PMID: 37845149
Background: The cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (E/T/I) is highly effective clinically for those with at least one F508del-CFTR allele. The effects of E/T/I on mucociliary clearance...
8.
Zemke A, Hilliam Y, Stapleton A, Kimple A, Goralski J, Shaffer A, et al.
Int Forum Allergy Rhinol
. 2023 Oct;
14(5):928-938.
PMID: 37837613
Background: Chronic rhinosinusitis (CRS) is common in individuals with cystic fibrosis (CF) and is marked by chronic inflammation and episodes of infection that negatively impact quality of life. Several studies...
9.
Kazmerski T, Stransky O, Wright C, Albanowski M, Pilewski J, Birru Talabi M, et al.
J Cyst Fibros
. 2023 Oct;
23(3):404-411.
PMID: 37833123
Background: People with cystic fibrosis (CF) are increasingly considering their reproductive goals. We developed MyVoice:CF, a web-based patient-centered reproductive decision support tool and assessed its implementation in CF care. Methods:...
10.
Mayer-Hamblett N, Clancy J, Jain R, Donaldson S, Fajac I, Goss C, et al.
Lancet Respir Med
. 2023 Sep;
11(10):932-944.
PMID: 37699421
The growing use of modulator therapies aimed at restoring cystic fibrosis transmembrane conductance regulator (CFTR) protein function in people with cystic fibrosis has fundamentally altered clinical trial strategies needed to...